FDA speaks on social media: No benefits without risks, even on Twitter

It's June. Three weeks to go until July 9, the FDA's self-imposed deadline for wrapping up its social media guidance. And now, pharma marketers are in luck: The agency has unveiled two more pieces of the puzzle. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.